Dr. Didier Leroy, Team Leader of Lead Discovery Technologies at Merck-Serono to present at GTCbio’s 3rd Protein Kinase in Drug Discovery Conference on May 4-5, 2008 in San Diego, CA

D

Dr. Didier Leroy, Team Leader of Lead Discovery Technologies, Geneva Research Center at Merck-Serono will be presenting at GTCbio’s 3rd Protein Kinase in Drug Discovery Conference on May 4-5, 2008 in San Diego, CA.

As the Team Leader at Merck-Serono, Dr. Leroy’s goal in oncology is to develop novel therapies that specifically target cancer cells and are more tolerable for patients. His research is focused on all aspects of disease pharmacology with the ultimate goal to increase patient survival and improve quality of life. In the Neurological, Autoimmune and Inflammatory disease areas, Dr. Leroy focuses on all aspects of disease biology and pharmacology research with the goal to identify novel therapies that provide symptomatic relief and slow or stop disease progression.

At the conference, Dr. Leroy will discuss the evolution of the major strategies and technologies that allowed the identification of kinase inhibitors with a potential use in oncology, neurology, inflammation and infectious diseases. The characteristics of compounds identified by molecular and cellular-based assays using radioactive, fluorescent and label free approaches will be revealed. Dr. Leroy will also discuss the progression of key molecules within the drug discovery pipeline following the early determination of DMPK/Tox parameters and molecular modes of action as well as the novelty and quality of newly identified kinase inhibitors according to the complexity of the technologies used from primary screening to Lead optimization steps.

GTCbio’s 3rd Protein Kinase in Drug Discovery Conference on May 5-6, 2008 in San Diego, CA will also cover Kinase Drug Design, Kinase Targets and Inhibitors in CNS Disorders, Oncology, and Inflammatory Disorders, as well as New Technologies in Screening and Identification of Targets and Inhibitors.

The conference also features presentations from other leading organizations such as Johnson & Johnson, Roche, Pfizer, Merck, GlaxoSmithKline, Salk Institute, AstraZeneca, Methylgene, UCSD, and many more. The full agenda is available online at www.gtcbio.com.

For more information including a detailed agenda, exhibitor opportunities and registration information visit http://gtcbio.com/userAgenda.aspx?id=121.

ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community. GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, [email protected]

About the author

By GTCbio